SP Ultimate
SP Ultimate, licence 80017445: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Pure Encapsulations
- NPN or DIN-HM
- 80017445
- Status
- Inactive licence
- Licence date
- 7 April 2010
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
annexe III, partie B (règlement (UE) 2022/2340). Regulation (EC) No 1925/2006, latest consolidated version, retrieved 21 October 2026.
- Conditions légales
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Prunus africana (Hook. f.) Kalkman: L'étiquetage doit comporter une mention recommandant de prendre conseil auprès d'un professionnel de santé.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Camellia sinensis Source : Feuille Extraction ratio : 20:1 Dry plant equivalent : 666 mg Potency : 65.0 % Catechins | 33.3 mg | Not calculated |
| Camellia sinensis Source : Feuille Potency : 23.0 % Epigallocatechin gallate | Not specified | Not calculated |
| Camellia sinensis Source : Feuille Potency : 7.0 % Caffeine | Not specified | Not calculated |
| Silybum marianum Source : Fruit Potency : 80.0 % Silymarin | 33.3 mg | Not calculated |
| Phytosterol complex Source : Soy Potency : 45.0 % Beta-sitosterol | 45.0 mg | Not calculated |
| Prunus africana Source : Écorce Potency : 2.5 % Total sterols | 33.3 mg | Not calculated |
| Vitamine C Source : Palmitate d'ascorbyle | 10.0 mg | Not calculated |
| Punica granatum Source : Fruit Potency : 5.0 % Ellagic acid | 16.7 mg | Not calculated |
Non-medicinal ingredients
Sorbitol, Hydroxypropyl methylcellulose, Dioxyde de silicium, Eau
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe masculin | Not specified | 2.0 Capsule | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in Herbal Medicine to help relieve the urologic symptoms (e.g. weak urine flow, incomplete voiding, frequent daytime and night time urination) associated with mild to moderate benign prostatic hyperplasia.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80017445
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.